210 related articles for article (PubMed ID: 27625304)
1. CHK1 as a therapeutic target to bypass chemoresistance in AML.
David L; Fernandez-Vidal A; Bertoli S; Grgurevic S; Lepage B; Deshaies D; Prade N; Cartel M; Larrue C; Sarry JE; Delabesse E; Cazaux C; Didier C; Récher C; Manenti S; Hoffmann JS
Sci Signal; 2016 Sep; 9(445):ra90. PubMed ID: 27625304
[TBL] [Abstract][Full Text] [Related]
2. Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitro.
Schenk EL; Koh BD; Flatten KS; Peterson KL; Parry D; Hess AD; Smith BD; Karp JE; Karnitz LM; Kaufmann SH
Clin Cancer Res; 2012 Oct; 18(19):5364-73. PubMed ID: 22869869
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.
Zhao J; Xie C; Edwards H; Wang G; Taub JW; Ge Y
Oncotarget; 2017 Jan; 8(4):6319-6329. PubMed ID: 28030834
[TBL] [Abstract][Full Text] [Related]
4. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
5. Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo.
Vincelette ND; Ding H; Huehls AM; Flatten KS; Kelly RL; Kohorst MA; Webster J; Hess AD; Pratz KW; Karnitz LM; Kaufmann SH
Sci Rep; 2019 Mar; 9(1):3617. PubMed ID: 30837643
[TBL] [Abstract][Full Text] [Related]
6. Cytosine Deaminase APOBEC3A Sensitizes Leukemia Cells to Inhibition of the DNA Replication Checkpoint.
Green AM; Budagyan K; Hayer KE; Reed MA; Savani MR; Wertheim GB; Weitzman MD
Cancer Res; 2017 Sep; 77(17):4579-4588. PubMed ID: 28655787
[TBL] [Abstract][Full Text] [Related]
7. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Zemanova J; Hylse O; Collakova J; Vesely P; Oltova A; Borsky M; Zaprazna K; Kasparkova M; Janovska P; Verner J; Kohoutek J; Dzimkova M; Bryja V; Jaskova Z; Brychtova Y; Paruch K; Trbusek M
Oncotarget; 2016 Sep; 7(38):62091-62106. PubMed ID: 27556692
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Webster JA; Tibes R; Morris L; Blackford AL; Litzow M; Patnaik M; Rosner GL; Gojo I; Kinders R; Wang L; Doyle LA; Huntoon CJ; Karnitz LM; Kaufmann SH; Karp JE; Smith BD
Leuk Res; 2017 Oct; 61():108-116. PubMed ID: 28957699
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Montano R; Chung I; Garner KM; Parry D; Eastman A
Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Mesa RA; Loegering D; Powell HL; Flatten K; Arlander SJ; Dai NT; Heldebrant MP; Vroman BT; Smith BD; Karp JE; Eyck CJ; Erlichman C; Kaufmann SH; Karnitz LM
Blood; 2005 Jul; 106(1):318-27. PubMed ID: 15784732
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation.
Samadder P; Suchánková T; Hylse O; Khirsariya P; Nikulenkov F; Drápela S; Straková N; Vaňhara P; Vašíčková K; Kolářová H; Binó L; Bittová M; Ovesná P; Kollár P; Fedr R; Ešner M; Jaroš J; Hampl A; Krejčí L; Paruch K; Souček K
Mol Cancer Ther; 2017 Sep; 16(9):1831-1842. PubMed ID: 28619751
[TBL] [Abstract][Full Text] [Related]
14. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
Boudny M; Trbusek M
Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
[TBL] [Abstract][Full Text] [Related]
15. The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia.
Di Tullio A; Rouault-Pierre K; Abarrategi A; Mian S; Grey W; Gribben J; Stewart A; Blackwood E; Bonnet D
Nat Commun; 2017 Nov; 8(1):1679. PubMed ID: 29162833
[TBL] [Abstract][Full Text] [Related]
16. Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis.
Tomic B; Smoljo T; Lalic H; Dembitz V; Batinic J; Batinic D; Bedalov A; Visnjic D
Sci Rep; 2022 Jul; 12(1):11344. PubMed ID: 35790845
[TBL] [Abstract][Full Text] [Related]
17. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
18. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
Lei H; Jin J; Liu M; Li X; Luo H; Yang L; Xu H; Wu Y
Leuk Res; 2018 Jan; 64():17-23. PubMed ID: 29149649
[TBL] [Abstract][Full Text] [Related]
19. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]